Focus: Corcym is a UK-based medical device company founded in 2024, specializing in cardiac implants and surgical instruments for valve replacement procedures. The company is pre-revenue and early-stage with a focused portfolio in cardiovascular disease.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Corcym represents a high-risk, high-reward early-stage opportunity for professionals willing to bet on a newly launched medical device company with established technology but unproven commercial execution.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead valve platform with multiple active trials and real-world registries supporting commercial adoption.
Help build intelligence for Corcym
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Corcym's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary aortic valve offering in active surgical replacement trial.
Expanding therapeutic scope beyond aortic to mitral indications with active clinical study.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo